Wednesday, 20 January 2021, 4:03 pm
The year 2021 is set to become quite a year for the
pharma companies leading the COVID-19 vaccine race, with
significant revenues on the line. As some of the most
significant players in the market, pharma giants Pfizer and
Moderna are set for the lion s share of 2021 vaccine
sales.
According to data presented by Finaria.it,
BioNTech-Pfizer and Moderna COVID-19 vaccines sales are
expected to generate $14.7bn in revenue by
2023.
Moderna COVID-19 Vaccine Sales Revenue to hit
$3.5B in 2021
The call for COVID-19 vaccines and
treatments has become louder than ever, with countries
worldwide facing the full force of the pandemic s second
Press Release – Psychic Ventures Ltd The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the …The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the lion’s share of 2021 vaccine sales.
According to data presented by Finaria.it, BioNTech-Pfizer and Moderna COVID-19 vaccines sales are expected to generate $14.7bn in revenue by 2023.
AstraZeneca, J&J COVID-19 shots must succeed to meet U S vaccination goal: Slaoui fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.